Movement Alert｜Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally

Market Focus05-22

On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA approval of its updated liquid biopsy test.

On May 21, the company announced that the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. The test integrates genomic and epigenomic profiling from a single blood draw, provides higher sensitivity to detect circulating tumor DNA, and covers a 100-times wider genomic footprint than the previously approved Guardant360 CDx. Results can be delivered within seven days. The stock rose approximately 5% on that news. The current pre-market decline erases those gains and more, suggesting the market may be reassessing the near-term commercial impact of the approval.

Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics to help advance cancer detection and treatment globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121559214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121559214","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally","media":"Market Focus","content":"<p><p>On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA approval of its updated liquid biopsy test.</p><p>On May 21, the company announced that the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. The test integrates genomic and epigenomic profiling from a single blood draw, provides higher sensitivity to detect circulating tumor DNA, and covers a 100-times wider genomic footprint than the previously approved Guardant360 CDx. Results can be delivered within seven days. The stock rose approximately 5% on that news. The current pre-market decline erases those gains and more, suggesting the market may be reassessing the near-term commercial impact of the approval.</p><p>Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics to help advance cancer detection and treatment globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-22 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA approval of its updated liquid biopsy test.</p><p>On May 21, the company announced that the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. The test integrates genomic and epigenomic profiling from a single blood draw, provides higher sensitivity to detect circulating tumor DNA, and covers a 100-times wider genomic footprint than the previously approved Guardant360 CDx. Results can be delivered within seven days. The stock rose approximately 5% on that news. The current pre-market decline erases those gains and more, suggesting the market may be reassessing the near-term commercial impact of the approval.</p><p>Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics to help advance cancer detection and treatment globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1121559214","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121559214","pubTimestamp":1779447884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动向提示|Guardant Health盘前跌8.48%FDA批准推动反弹后回调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On May 22, Guardant Health fell 8.48% in pre-market trading, trading at $118.01/share, with trading volume of $36,900. The decline comes one session after the stock rallied over 5% following FDA approval of its updated liquid biopsy test.On May 21, the company announced that the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. The test integrates genomic and epigenomic profiling from a single blood draw, provides higher sensitivity to detect circulating tumor DNA, and covers a 100-times wider genomic footprint than the previously approved Guardant360 CDx. Results can be delivered within seven days. The stock rose approximately 5% on that news. The current pre-market decline erases those gains and more, suggesting the market may be reassessing the near-term commercial impact of the approval.Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics to help advance cancer detection and treatment globally.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121559214","isCrawlerRequest":true}